Literature DB >> 16443557

Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.

Mahito Misawa1, Shunro Kai, Masaya Okada, Toshiyuki Nakajima, Kaori Nomura, Takeshi Wakae, Akinari Toda, Hisayuki Itoi, Hiroyuki Takatsuka, Takeyoshi Itsukuma, Keisuke Nishioka, Yoshihiro Fujimori, Hiroyasu Ogawa, Hiroshi Hara.   

Abstract

Reduced-intensity (RI) conditioning followed by cord blood transplantation (CBT) is a new treatment modality, but failure to engraft is a major concern. We describe 12 patients with advanced hematologic malignancies who underwent RI conditioning and CBT with a conditioning regimen consisting of 200 mg/m(2) fludarabine (Flu), 50 mg/kg cyclophosphamide (CY), and 3 Gy total body irradiation (TBI). Cyclosporin A and/or methotrexate were used for graft-versus-host disease prophylaxis. Cord blood grafts were not mismatched for more than 2 serologically defined HLA alleles but were later found by high-resolution DNA typing to be mismatched for 2 to 4 alleles in most cases. Short tandem repeat analysis of bone marrow cells at day 14 showed complete donor chimerism in 6 of the patients and mixed chimerism in 5, indicating rapid engraftment in the bone marrow, whereas the remaining patient experienced graft rejection. Neutrophil recovery was achieved at a median of day 17 (range, days 11-24) in 10 of the 11 patients with marrow chimerism at day 14. Of these 10 patients, however, transplantation-related mortality within 100 days occurred in 4 patients who showed failed platelet recovery and a lack of durable engraftment. Overall survival and disease-free survival rates were 41.7% and 33.3%, respectively. These results show that CB mismatched at 2 to 4 HLA alleles and transplanted with the Flu/CY/3 Gy TBI regimen is able to engraft in the bone marrow as early as day 14.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443557     DOI: 10.1532/IJH97.05124

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation.

Authors:  O Olerup; H Zetterquist
Journal:  Tissue Antigens       Date:  1992-05

2.  Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma.

Authors:  Koichiro Yuji; Shigesaburo Miyakoshi; Daisuke Kato; Yuji Miura; Tomohiro Myojo; Naoko Murashige; Yukiko Kishi; Kazuhiro Kobayashi; Eiji Kusumi; Hiroto Narimatsu; Tamae Hamaki; Tomoko Matsumura; Masahiro Kami; Takahiro Fukuda; Shigeru Masuo; Kazuhiro Masuoka; Atsushi Wake; Junichi Ueyama; Akiko Yoneyama; Ko Miyamoto; Haruhisa Nagoshi; Michio Matsuzaki; Shinichi Morinaga; Yoshitomo Muto; Yoichi Takeue; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2005-04       Impact factor: 5.742

3.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

4.  Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.

Authors:  A H Elmaagacli; D W Beelen; G Trenn; O Schmidt; M Nahler; U W Schaefer
Journal:  Bone Marrow Transplant       Date:  1999-04       Impact factor: 5.483

5.  The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis.

Authors:  Hirokazu Nishihira; Koji Kato; Keiichi Isoyama; Tsuneo A Takahashi; Shunro Kai; Shunichi Kato; Minoko Takanashi; Norihiro Sato; Hiroyuki Sato; Kohichi Kitajima; Tomoki Naoe; Hidehiko Saito
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

6.  Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group.

Authors:  E Gluckman; V Rocha; A Boyer-Chammard; F Locatelli; W Arcese; R Pasquini; J Ortega; G Souillet; E Ferreira; J P Laporte; M Fernandez; C Chastang
Journal:  N Engl J Med       Date:  1997-08-07       Impact factor: 91.245

7.  Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment.

Authors:  S A Schichman; P Suess; A M Vertino; P S Gray
Journal:  Bone Marrow Transplant       Date:  2002-02       Impact factor: 5.483

8.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Jeffrey S Miller; John E Wagner
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

9.  Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice.

Authors:  Eliane Gluckman; Vanderson Rocha; William Arcese; Gérard Michel; Guillermo Sanz; Ka-Wah Chan; Tsuneo A Takahashi; Juan Ortega; Alexandra Filipovich; Franco Locatelli; Shigetaka Asano; Franca Fagioli; Marcus Vowels; Anne Sirvent; Jean-Philippe Laporte; Karin Tiedemann; Sergio Amadori; Manuel Abecassis; Pierre Bordigoni; Blanca Diez; Peter J Shaw; Ajay Vora; Maurizio Caniglia; Federico Garnier; Irina Ionescu; Joan Garcia; Gesine Koegler; Paolo Rebulla; Sylvie Chevret
Journal:  Exp Hematol       Date:  2004-04       Impact factor: 3.084

10.  Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens.

Authors:  Nelson J Chao; Liang-Piu Koh; Gwynn D Long; Cristina Gasparetto; Mitchell Horwitz; Ashley Morris; Martha Lassiter; Keith M Sullivan; David A Rizzieri
Journal:  Biol Blood Marrow Transplant       Date:  2004-08       Impact factor: 5.742

View more
  12 in total

1.  Future alternative therapies for β-thalassemia.

Authors:  Stefano Rivella; Eliezer Rachmilewitz
Journal:  Expert Rev Hematol       Date:  2009-12-01       Impact factor: 2.929

2.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Authors:  Claudio G Brunstein; Ephraim J Fuchs; Shelly L Carter; Chatchada Karanes; Luciano J Costa; Juan Wu; Steven M Devine; John R Wingard; Omar S Aljitawi; Corey S Cutler; Madan H Jagasia; Karen K Ballen; Mary Eapen; Paul V O'Donnell
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

3.  Detection of donor-derived CMV-specific T cells in cerebrospinal fluid in a case of CMV meningoencephalitis after cord blood stem cell transplantation.

Authors:  Kazuhiro Ikegame; Ruri Kato; Tatsuya Fujioka; Masaya Okada; Katsuji Kaida; Shinichi Ishii; Satoshi Yoshihara; Takayuki Inoue; Kyoko Taniguchi; Hiroya Tamaki; Toshihiro Soma; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2012-12-29       Impact factor: 2.490

4.  Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.

Authors:  Hongliang Sun; Ying Tsai; Irena Nowak; Jane Liesveld; Yuhchyau Chen
Journal:  Stem Cell Res       Date:  2012-05-14       Impact factor: 2.020

5.  Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes.

Authors:  Claudio G Brunstein; Mary Eapen; Kwang Woo Ahn; Frederick R Appelbaum; Karen K Ballen; Richard E Champlin; Corey Cutler; Fangyu Kan; Mary J Laughlin; Robert J Soiffer; Daniel J Weisdorf; Anne Woolfrey; John E Wagner
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

6.  Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.

Authors:  F Ostronoff; F Milano; T Gooley; J A Gutman; P McSweeney; F B Petersen; B M Sandmaier; R Storb; C Delaney
Journal:  Bone Marrow Transplant       Date:  2012-12-17       Impact factor: 5.483

7.  Cord blood transplantation using minimum conditioning regimens for patients with hematologic malignancies complicated by severe infections.

Authors:  Takeshi Yamashita; Chiharu Sugimori; Ken Ishiyama; Hirohito Yamazaki; Hirokazu Okumura; Yukio Kondo; Akiyoshi Takami; Shinji Nakao
Journal:  Int J Hematol       Date:  2008-12-25       Impact factor: 2.490

8.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Authors:  Claudio G Brunstein; Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; John E Wagner
Journal:  Blood       Date:  2007-06-14       Impact factor: 22.113

9.  Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study.

Authors:  Judith A E Somers; Eric Braakman; Bronno van der Holt; Eefke J Petersen; Erik W A Marijt; Cynthia Huisman; Kees Sintnicolaas; Machteld Oudshoorn; Marlies E Groenendijk-Sijnke; Anneke Brand; Jan J Cornelissen
Journal:  Haematologica       Date:  2014-08-08       Impact factor: 9.941

10.  A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

Authors:  M Gotoh; S Yoshizawa; S Katagiri; T Suguro; M Asano; T Kitahara; D Akahane; S Okabe; T Tauchi; Y Ito; K Ohyashiki
Journal:  Bone Marrow Transplant       Date:  2014-04-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.